<?xml version='1.0' encoding='utf-8'?>
<document id="25280976"><sentence text="Pharmacokinetic drug-drug interaction of calcium channel blockers with cyclosporine in hematopoietic stem cell transplant children."><entity charOffset="41-48" id="DDI-PubMed.25280976.s1.e0" text="calcium" /><entity charOffset="71-83" id="DDI-PubMed.25280976.s1.e1" text="cyclosporine" /><pair ddi="false" e1="DDI-PubMed.25280976.s1.e0" e2="DDI-PubMed.25280976.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25280976.s1.e0" e2="DDI-PubMed.25280976.s1.e1" /></sentence><sentence text="Cyclosporine (CsA) is frequently responsible for hypertension in bone marrow transplant children"><entity charOffset="0-12" id="DDI-PubMed.25280976.s2.e0" text="Cyclosporine" /><entity charOffset="14-17" id="DDI-PubMed.25280976.s2.e1" text="CsA" /><pair ddi="false" e1="DDI-PubMed.25280976.s2.e0" e2="DDI-PubMed.25280976.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25280976.s2.e0" e2="DDI-PubMed.25280976.s2.e1" /></sentence><sentence text=" Calcium channel blockers (CCBs) are considered to be the best treatment for CsA-induced hypertension, but they may alter the exposure and the effect of CsA by inhibiting the CYP3A4 pathway of CsA metabolism or P-gp"><entity charOffset="1-8" id="DDI-PubMed.25280976.s3.e0" text="Calcium" /><entity charOffset="77-83" id="DDI-PubMed.25280976.s3.e1" text="CsA" /><entity charOffset="153-159" id="DDI-PubMed.25280976.s3.e2" text="CsA" /><entity charOffset="193-199" id="DDI-PubMed.25280976.s3.e3" text="CsA" /><pair ddi="false" e1="DDI-PubMed.25280976.s3.e0" e2="DDI-PubMed.25280976.s3.e0" /><pair ddi="false" e1="DDI-PubMed.25280976.s3.e0" e2="DDI-PubMed.25280976.s3.e1" /><pair ddi="false" e1="DDI-PubMed.25280976.s3.e0" e2="DDI-PubMed.25280976.s3.e2" /><pair ddi="false" e1="DDI-PubMed.25280976.s3.e0" e2="DDI-PubMed.25280976.s3.e3" /><pair ddi="false" e1="DDI-PubMed.25280976.s3.e1" e2="DDI-PubMed.25280976.s3.e1" /><pair ddi="false" e1="DDI-PubMed.25280976.s3.e1" e2="DDI-PubMed.25280976.s3.e2" /><pair ddi="false" e1="DDI-PubMed.25280976.s3.e1" e2="DDI-PubMed.25280976.s3.e3" /><pair ddi="false" e1="DDI-PubMed.25280976.s3.e2" e2="DDI-PubMed.25280976.s3.e2" /><pair ddi="false" e1="DDI-PubMed.25280976.s3.e2" e2="DDI-PubMed.25280976.s3.e3" /></sentence><sentence text=" However, the inhibitory effect on CYP3A4 may vary among CCBs" /><sentence text="" /><sentence text="This study aimed to quantify the pharmacokinetic drug-drug interaction between CsA and nicardipine, amlodipine, and lacidipine"><entity charOffset="87-98" id="DDI-PubMed.25280976.s6.e0" text="nicardipine" /><entity charOffset="100-110" id="DDI-PubMed.25280976.s6.e1" text="amlodipine" /><entity charOffset="116-126" id="DDI-PubMed.25280976.s6.e2" text="lacidipine" /><entity charOffset="79-88" id="DDI-PubMed.25280976.s6.e3" text="CsA" /><pair ddi="false" e1="DDI-PubMed.25280976.s6.e3" e2="DDI-PubMed.25280976.s6.e3" /><pair ddi="false" e1="DDI-PubMed.25280976.s6.e3" e2="DDI-PubMed.25280976.s6.e0" /><pair ddi="false" e1="DDI-PubMed.25280976.s6.e3" e2="DDI-PubMed.25280976.s6.e1" /><pair ddi="false" e1="DDI-PubMed.25280976.s6.e3" e2="DDI-PubMed.25280976.s6.e2" /><pair ddi="false" e1="DDI-PubMed.25280976.s6.e0" e2="DDI-PubMed.25280976.s6.e0" /><pair ddi="false" e1="DDI-PubMed.25280976.s6.e0" e2="DDI-PubMed.25280976.s6.e1" /><pair ddi="false" e1="DDI-PubMed.25280976.s6.e0" e2="DDI-PubMed.25280976.s6.e2" /><pair ddi="false" e1="DDI-PubMed.25280976.s6.e1" e2="DDI-PubMed.25280976.s6.e1" /><pair ddi="false" e1="DDI-PubMed.25280976.s6.e1" e2="DDI-PubMed.25280976.s6.e2" /></sentence><sentence text=" In all, 51 children who received CsA and CCB concomitantly were included"><entity charOffset="34-36" id="DDI-PubMed.25280976.s7.e0" text="CsA" /></sentence><sentence text="" /><sentence text="Dose-normalized CsA trough blood concentrations significantly increased in patients treated with nicardipine and amlodipine, whereas they remained stable in patients treated with lacidipine"><entity charOffset="97-108" id="DDI-PubMed.25280976.s9.e0" text="nicardipine" /><entity charOffset="113-123" id="DDI-PubMed.25280976.s9.e1" text="amlodipine" /><entity charOffset="179-189" id="DDI-PubMed.25280976.s9.e2" text="lacidipine" /><entity charOffset="16-25" id="DDI-PubMed.25280976.s9.e3" text="CsA" /><pair ddi="false" e1="DDI-PubMed.25280976.s9.e3" e2="DDI-PubMed.25280976.s9.e3" /><pair ddi="false" e1="DDI-PubMed.25280976.s9.e3" e2="DDI-PubMed.25280976.s9.e0" /><pair ddi="false" e1="DDI-PubMed.25280976.s9.e3" e2="DDI-PubMed.25280976.s9.e1" /><pair ddi="false" e1="DDI-PubMed.25280976.s9.e3" e2="DDI-PubMed.25280976.s9.e2" /><pair ddi="false" e1="DDI-PubMed.25280976.s9.e0" e2="DDI-PubMed.25280976.s9.e0" /><pair ddi="false" e1="DDI-PubMed.25280976.s9.e0" e2="DDI-PubMed.25280976.s9.e1" /><pair ddi="false" e1="DDI-PubMed.25280976.s9.e0" e2="DDI-PubMed.25280976.s9.e2" /><pair ddi="false" e1="DDI-PubMed.25280976.s9.e1" e2="DDI-PubMed.25280976.s9.e1" /><pair ddi="false" e1="DDI-PubMed.25280976.s9.e1" e2="DDI-PubMed.25280976.s9.e2" /></sentence><sentence text="" /><sentence text="Because lacidipine appears to have no effect on CsA exposure, it may be the best option among CCBs for treating high blood pressure caused by CsA in children"><entity charOffset="8-18" id="DDI-PubMed.25280976.s11.e0" text="lacidipine" /><entity charOffset="48-57" id="DDI-PubMed.25280976.s11.e1" text="CsA" /><entity charOffset="142-151" id="DDI-PubMed.25280976.s11.e2" text="CsA" /><pair ddi="false" e1="DDI-PubMed.25280976.s11.e0" e2="DDI-PubMed.25280976.s11.e0" /><pair ddi="false" e1="DDI-PubMed.25280976.s11.e0" e2="DDI-PubMed.25280976.s11.e1" /><pair ddi="false" e1="DDI-PubMed.25280976.s11.e0" e2="DDI-PubMed.25280976.s11.e2" /><pair ddi="false" e1="DDI-PubMed.25280976.s11.e1" e2="DDI-PubMed.25280976.s11.e1" /><pair ddi="false" e1="DDI-PubMed.25280976.s11.e1" e2="DDI-PubMed.25280976.s11.e2" /></sentence><sentence text="" /></document>